01:18 , Dec 13, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived liver and bile duct cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by treating patient tumor samples with collagenase and deoxyribonuclease I (DNASE1) to...
21:21 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Alidornase alfa: Interim Ph II data

Interim data from an open-label, Israeli Phase II trial in 13 evaluable CF patients previously treated with Pulmozyme dornase alfa showed that once-daily 2.5 mg inhaled alidornase alfa for 28 days led to a 4.1...
01:45 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

AIR DNase: Completed Ph II enrollment

Protalix completed enrollment of 15 patients switching over from Pulmozyme dornase alfa in an open-label, Israeli Phase II trial evaluating 2.5 mg inhaled AIR DNase once daily for 28 days. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX),...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting neutrophil extracellular traps (NETs) with DNASE1 or other agents could help treat metastatic breast cancer. In primary tumor samples from 20 patients with metastatic...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

AIR DNase: Phase II started

Protalix began an open-label, Israeli Phase II trial to evaluate 2.5 mg inhaled AIR DNase once daily for 28 days in 15 patients switching over from Pulmozyme dornase alfa. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Deoxyribonuclease I like 3 (DNASE1L3)

Autoimmune disease INDICATION: Lupus Patient sample and mouse studies suggest DNASE1L3 could help treat lupus caused by mutations in the gene. In vitro, sera from DNASE1L3-deficient mice and lupus patients digested less DNA from apoptotic cells and...
07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Guiding the way

George Church's Harvard Medical School lab is addressing head-on one of the biggest limitations of CRISPR-based gene editing: Until the tech has been proven to cut only where and when needed, it won't make the...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

PulmoXen: Phase I data

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the trial, plans to start...
07:00 , Jun 5, 2000 |  BC Week In Review  |  Company News

Universitatsklinikum Essen other research news

Essen researchers and colleagues published in Nature Genetics that mice deficient in DNase l develop symptoms of the autoimmune disease systemic lupus erythematosus (SLE), including anti-nuclear antibodies and glomerulonephritis. Also, DNase 1 activity was found...